Q2 2020 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Greetings, and welcome to Navidea Biopharmaceuticals Q2 2020 Earnings and Business Update Conference Call. (Operator Instructions) Please note, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Jed Latkin, CEO. Thank you. You may begin.
Thank you, Devin. First off, I just wanted to say that this call is being webcast live on our website, ir.navidea.com, and a replay will be made available. Following prepared remarks, we'll be conducting a question-and-answer segment.
During the course of this conference call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Navidea's molecular diagnostics and immunotherapeutics, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters as well as the impact of the COVID-19 pandemic on
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |